Press Releases

InVivo Therapeutics Announces Closing of Public Offering of Common Stock

Published: November 22, 2019

CAMBRIDGE, Mass. (November 22, 2019) – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therapeutics. The offering closed on November 22, 2019. H.C. Wainwright & Co. acted as exclusive placement agent for the offering. A registration statement on Form S-3 (File No. 333-234353) relating to the shares of common stock offered […]

View Article
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock

Published: November 21, 2019

CAMBRIDGE, Mass. (November 21, 2019) – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are expected to be $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therapeutics. The offering is expected to close on or about November 22, 2019, subject to customary closing conditions. H.C. Wainwright & Co., is acting as exclusive placement agent in connection with the offering. A registration statement […]

View Article
InVivo Therapeutics Announces Proposed Public Offering of Common Stock

Published: November 18, 2019

CAMBRIDGE, Mass. (November 18, 2019) – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The shares described above will be offered pursuant to a shelf registration statement on Form S-3 (No. […]

View Article
InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors

Published: November 12, 2019

CAMBRIDGE, Mass. (November 12, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent. “Dr. Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations, to strategic planning and capital market transactions, will be a […]

View Article
InVivo Therapeutics Provides Enrollment Update for INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury

Published: October 22, 2019

– First Five Patients Enrolled into Study, Reaching 25% Completion of Targeted Enrollment – CAMBRIDGE, Mass. (October 22, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a total of five patients have been enrolled into the INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), bringing the study to 25% completion of targeted enrollment. The first patient was enrolled into the INSPIRE 2.0 Study in May of 2019, and 14 sites are currently open for enrollment into the study. Richard […]

View Article
InVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal Cord

Published: July 16, 2019

CAMBRIDGE, Mass. (July 16, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a manuscript in the peer-reviewed journal Spinal Cord describing its CONTEMPO registry study data. The CONTEMPO registry study, part of the Company’s IDE submission for the Neuro-Spinal Scaffold™, was designed to provide comprehensive natural history benchmarks for the Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study included neurological recovery data from three registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE 1.0 Study. The registries included the North American Clinical Trials Network (NACTN), European Multicenter Study about Spinal […]

View Article
InVivo Therapeutics Announces Postponement of Annual Meeting

Published: July 12, 2019

CAMBRIDGE, Mass. (July 12, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders.  The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the shares of the Company’s outstanding common stock entitled to vote at the meeting were present in person or by proxy on July 11, 2019, and the Company therefore determined that a quorum did not exist.  The Company anticipates publicly announcing a new record date and the new […]

View Article
InVivo Therapeutics Announces Adjournment of Annual Meeting Scheduled to Reconvene on July 2, 2019

Published: June 14, 2019

–      Company urgently encourages stockholders to vote     – CAMBRIDGE, Mass. (June 14, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Annual Meeting will be reconvened July 2, 2019 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 25, 2019. It has come to the Company’s attention that […]

View Article
InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury

Published: May 29, 2019

CAMBRIDGE, Mass. (May 29, 2019) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). “Having the first two patients enrolled into the INSPIRE 2.0 Study is a critical milestone for the company and for the spinal cord injury patient population, as there continues to be inadequate treatment options for these patients. With eight clinical sites now open for enrollment, we remain optimistic about continuing to […]

View Article
InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: April 17, 2019

– E-poster Presented at the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting – CAMBRIDGE, Mass. (April 17, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, “Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.